Why is Alembic Pharma falling/rising?

As of 09-Jul, Alembic Pharmaceuticals Ltd. is currently priced at 986.30, reflecting a decline of 12.3 points or 1.23%. The stock has underperformed its sector today by 1.43% and has experienced a consecutive fall over the last two days, resulting in a total decrease of 1.37% during this period. Despite having a higher performance in terms of moving averages over the 20, 50, and 100-day periods, it remains lower than the 5-day and 200-day moving averages. The stock's delivery volume has also decreased significantly, falling by 39.92% against the 5-day average, indicating reduced investor participation. While the company has a low Debt to EBITDA ratio of 0.67 and a respectable ROCE of 11.5, its profits have declined by 7% over the past year, contributing to a negative sentiment around the stock.
In the broader market context, Alembic Pharmaceuticals has seen a short-term return of -0.34% over the past week, while the benchmark Sensex has gained 0.15%. This underperformance is further highlighted by the stock's year-to-date decline of 6.88%, contrasting sharply with the Sensex's increase of 6.91%. The company's long-term growth prospects appear poor, with an annual operating profit decline of 7.30% over the last five years and negative results reported in March, including a significant drop in PAT. Although the stock is trading at a discount compared to its peers, the high institutional holdings at 20.37% suggest that these investors may be cautious given the company's recent financial struggles.